TITLE

Aspirin, warfarin may reduce thromboembolic events in multiple myeloma

PUB. DATE
March 2011
SOURCE
Hem/Onc Today;3/25/2011, Vol. 12 Issue 6, p14
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports that fixed-dose warfarin or aspirin showed comparable efficiency as low-molecular-weight heparin in cutting the risk for thromboembolic events in myeloma patients who received regimens with thalidomide, which is based on a study involving 659 patients.
ACCESSION #
62393649

 

Related Articles

  • Thromboprophylaxis with LMWH, warfarin, low-dose aspirin, safe in newly diagnosed multiple myeloma.  // Hem/Onc Today;1/10/2010, Vol. 11 Issue 1, p18 

    This article focuses on a study which investigated the efficacy and safety of thromboprophylaxis with low-molecular weight heparin, warfarin or low-dose aspirin in preventing venous thromboembolism in patients with multiple myeloma.

  • Recurrent VTE prevented with long-term, low-intensity warfarin therapy. Traynor, Kate // American Journal of Health-System Pharmacy;4/1/2003, Vol. 60 Issue 7, p635 

    Discusses the use of long-term, low-intensity warfarin therapy for preventing recurrent venous thromboembolism. Safety and effectiveness of warfarin; Warfarin dosage; Bleeding complications.

  • Prophylactic Anticoagulant Therapy in the Orthopedic Patient. Neu Jr., Leo T.; Waterfield, Jim R.; Ash, Charles J. // Annals of Internal Medicine;Mar65, Vol. 62 Issue 3, p463 

    Focuses on a study of orthopedic patients who suffered trauma of the pelvis and lower extremities, to determine the value of routine prophylactic warfarin sodium anticoagulation in the prevention of thromboembolic phenomena. Significance of the variation between anticoagulated patients from the...

  • Regimen recaptured responses in heavily pretreated multiple myeloma.  // Hem/Onc Today;10/25/2013, Vol. 14 Issue 20, p44 

    The article presents the results of a phase two study as of late October 2013, which showed that the combination of panobinostat, bortezomib and dexamethasone is effective in heavily pretreated patients with bortezomib-refractory multiple myeloma.

  • 12. Vaccination strategies in multiple myeloma.  // Hematology Journal;2003 Supplement, Vol. 4 Issue 1, pS267 

    The Hematology Journal (2003) 4, S267-S272. doi:10.1038/sj.thj.6200292

  • Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant-ineligible patients with multiple myeloma: a meta-analysis. Kapoor, P.; Rajkumar, S. V.; Dispenzieri, A.; Gertz, M. A.; Lacy, M. Q.; Dingli, D.; Mikhael, J. R.; Roy, V.; Kyle, R. A.; Greipp, P. R.; Kumar, S.; Mandrekar, S. J. // Leukemia (08876924);Sep2011, Vol. 25 Issue 9, p1523 

    A correction to the article "Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant-ineligible patients with multiple myeloma: a meta-analysis" that was published online on January 14, 2011 is presented.

  • Heparin prevents recurrent VTE in cancer patients. Clenney, Timothy L.; Viera, Anthony J. // Journal of Family Practice;Nov2003, Vol. 52 Issue 11, p843 

    In a study of 676 adults with active cancer and newly diagnosed venous thromboembolism (VTE) it was found that the use of low-molecular-weight heparin is an effective approach for the prevention of VTE. The subjects were divided into two groups, the heparin-dalteparin and warfarin groups....

  • Fixed minidose warfarin doesn't prevent stroke in patients with atrial fib.  // Modern Medicine;Nov98, Vol. 66 Issue 11, p27 

    Presents an abstract of the study `Effectiveness of Fixed Minidose Warfarin in the Prevention of Thromboembolism and Vascular Death in Nonrheumatic Atrial Fibrillation,' by V. Pengo, A. Zasso, F. Barbero et al, which appeared in the `American Journal of Cardiology' dated August 15, 1998.

  • For blood clots associated with heart valve replacement.  // Modern Medicine;Jul94, Vol. 62 Issue 7, p29 

    Reports on the US Food and Drug Administration's (FDA) approval of the anticoagulant crystalline warfarin sodium for use in preventing and treating blood clots associated with prosthetic heart valve replacement. Reduction of the incidence of thromboembolism in patients with mechanical heart...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics